BIOSPAIN 2026

This round table will explore the growing range of alternative funding instruments available to innovative biotech SMEs, from public equity markets to emerging deeptech investment funds backed by public-private initiatives.
Moderated by Óscar Salazar (Euro-Funding), the discussion will bring together representatives from BME Growth, ICO AXIS, and a listed Spanish biotech company to share practical insights on how different financing options can support sustainable growth at different stages of a company's journey. Panelists will discuss how BME Growth can serve as a strategic financing platform for innovative SMEs, address common misconceptions and concerns surrounding stock market listings, and share first-hand experiences of accessing public markets. The conversation will also examine the role of new deeptech funds in closing financing gaps and complementing traditional investment sources.
Attendees will gain a clearer understanding of how alternative financing mechanisms can expand the capital toolbox available to biotech companies, helping founders and executives make informed decisions as they scale their businesses and navigate an increasingly diverse funding landscape.

Meet early stage companiesseeking seed/series A funding

Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.

---

• Backpacked-Antibody platform  – Izaskun Morillo, Postdoctoral Researcher
• Exitium Therapeutics  – Angélica Figueroa Conde-Valvís, CSO
• Korum Diagnostics  – Carla Ferrero Ruedas, CEO
• Lumina  – Guillem Loren, CEO
• Platelet Biotechnologies S.l.  – Andrea Acebes Huerta, CEO & Cofounder

Meet innovative companies developing Advanced Therapy Medicinal Products, which are innovative drugs for human used based on genes, cells or tissue engineering.

Start-ups will have the opportunity to present their business plans to a panel of investors. Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2026. 

---

Presenting companies:

• Amets Biotechnology  – Laia Trigueros Motos, CEO
• Golden Gate Biotech - Jascha Blobel, CEO
  
• Miramoon Pharma   –  Amalia Capilla,  CEO
  
• Nocturna Therapeutics   –   Miriam Corredor, CEO
• Peaches S.l.   –   Francesca Sarno, CSO
• Popcorn Therapeutics –  Iker Ausejo Mauleon,COO
• Tetraneuron SL   –   Ángel Lucio Pereira, CEO

Spain is doubling down on early-stage innovation with the launch of the Innvierte Deep-Tech & Tech Transfer programme, led by CDTI Innovación under the Ministry of Science, Innovation and Universities (MICIU), in collaboration with the European Investment Fund. With a total allocation of €353 million targeting early-stage technologies (TRL 2–4), the initiative aims to address Spain’s critical funding gap between research and commercialization—unlocking the potential of universities, research centers, and spin-offs.
This round table will explore how public-private co-investment models—such as the recent €30 million commitment to the Montana Children’s Health Fund, managed by Ship2B Ventures—can help catalyze a stronger deep-tech ecosystem. Bringing together perspectives from public investors, fund managers, and the European Investment Bank’s EIC Accelerator programme, the discussion will examine how institutional capital and blended financing can de-risk early innovation, strengthen technology transfer, and help breakthrough science reach the market.
Panelists will discuss the key challenges facing deep-tech ventures in Spain, from bridging the gap between research and investability to accessing the right mix of grants, equity, and institutional capital. The conversation will also explore how European-level instruments such as the EIC Accelerator can complement national initiatives and provide a pathway for high-potential companies to scale beyond their domestic markets.
Key questions include: How can Spain better align financial instruments with the needs of deep-tech entrepreneurs? What lessons can be drawn from the first Innvierte transaction? How can national and European funding mechanisms work together more effectively? And how can investors, corporates, universities, and public actors collaborate to accelerate the journey from lab to market and build globally competitive companies?
The session is designed for investors, fund managers, technology transfer offices, policymakers, corporates, and entrepreneurs seeking to understand and engage with Spain’s evolving deep-tech financing landscape—and the opportunities emerging at the intersection of national and European capital.

Mapping where the next therapeutic breakthroughs are emerging in Spain—key institutions, technologies and talent—and how to access and translate them into investment and company-building opportunities.

A guided tour of Spain’s biomedical frontier: where tomorrow’s therapies are being born, who’s driving them, which technologies enable them, and how to convert those breakthroughs into investment and company-building opportunities

Each company will be given a six-minute spotlight to unveil investment opportunities in drug development and delivery—six minutes to ignite interest and sketch the future of medicine.

Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.

---

• Vaxdyn – Juan José Infante Viñolo, CEO
  
• FatrixGel  – Pablo Sánchez-Rey Chiapasco, CEO & Founder
• Flavii Therapeutics  – Ariadna Boloix Amenós & Ainia Bellver , CEO & CSO & Co-founders
• Gate2brain – Mertixell Teixidó Turà, CEO & CSO
• i+Med S.coop –  Andrea Zapater Matute, R&D Business Developer
• MIMO BIOSCIENCES  – Jessika Valero Gonzalez,. Business Development Director
• Nanogrow Biotech – Nicolás Galmarini Galmarini, CEO & Co-founder
• Nostrum Biodiscovery –Marie-Eve Beaulieu, General Manager
• Olavide Neuron STX S.L. (ONESTX) – Ángel Cebolla Ramírez, CEO
• Ploid AI Biotech - Adolfo Gastalver, Co-Founder & CEO
• Resistia – Ignacio Massone, CEO & Co-founder
• Molefy Pharma - Tania Ortuño, Head of Operations

• Beatriz Llamusi
• https://www.linkedin.com/in/beatriz-llamusi-6b463a14a/
• CSO at Arthex